|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1258658321 |
| 003 |
OCoLC |
| 005 |
20231120010550.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
210702s2021 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OCLCO
|d EBLCP
|d OCLCF
|d NLE
|d OCLCO
|d OCLCQ
|d COM
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780323900799
|q (electronic bk.)
|
| 020 |
|
|
|a 0323900798
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323855037
|
| 020 |
|
|
|z 0323855032
|
| 035 |
|
|
|a (OCoLC)1258658321
|
| 050 |
|
4 |
|a RS199.5
|
| 082 |
0 |
4 |
|a 615/.6
|2 23
|
| 245 |
0 |
0 |
|a Advanced drug delivery systems in the management of cancer /
|c edited by Kamal Dua [and more].
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Intro -- Advanced Drug Delivery Systems in the Managementof Cancer -- Copyright -- Dedication -- Contents -- Contributors -- Editor biographies -- Chapter 1 Introduction to cancer cell biology -- 1 Introduction -- 2 Types of cancer -- 3 Pathophysiology of cancer -- 3.1 Sustained multiplication (proliferative) signaling -- 3.2 Shunning of anti-growth signals -- 3.3 Avoidance of immune annihilation (destruction) -- 3.4 Avoidance of apoptosis -- 3.5 Tissue invasion and metastasis -- 3.6 Extended (sustained) tumor angiogenesis -- 3.7 Endless multiplication (replication) potential
|
| 505 |
8 |
|
|a 3.8 Deregulation of cell energetics -- 3.9 Oncogenes and tumor suppressor genes -- 3.10 Breast cancer biology -- 3.11 Gastric cancer biology -- 3.12 Pancreatic cancer biology -- 3.13 Lung cancer biology -- 3.14 Leukemia biology -- References -- Chapter 2 Current practice in cancer pharmacotherapy -- 1 Introduction -- 1.1 Lung -- 1.2 Breast (female) -- 1.3 Prostate -- 1.4 Colon -- 1.5 Skin -- 2 Conclusions -- References -- Chapter 3 Current practices in oncology drug delivery -- 1 Introduction -- 1.1 Historical background -- 1.2 Ancient theories about cancer
|
| 505 |
8 |
|
|a 1.3 Description and epidemiology of cancer -- 2 Past therapeutic approaches in cancer (1900 and earlier) -- 3 Current approaches of drug delivery -- 3.1 Targeted therapy in cancer -- 3.1.1 Molecular targeted therapy -- 3.1.2 Monoclonal antibodies -- 3.1.3 Immunotoxins -- 3.2 Gene therapy -- 3.2.1 Gene therapy in clinics -- 3.3 Bacterial-mediated therapy -- 3.4 Nanomedicine -- 3.5 Immune checkpoint inhibitors -- 3.6 Radiomics and pathomics -- 3.6.1 Combining radiomics and pathomics with genomics -- 3.6.2 Combining radiomics and pathomics with artificial intelligence
|
| 505 |
8 |
|
|a 3.6.3 Combining radiomics and pathomics with tumor markers -- 3.6.4 Combining radiomics with pathomics immunological detection -- 3.7 Theranostics -- 4 Future directions -- References -- Chapter 4 Emerging need of advanced drug delivery systems in cancer -- 1 Introduction -- 2 Multidrug resistance in cancer cells -- 3 Toxic effects of chemotherapy -- 4 Hazardous effects of radiation oncology -- 5 Polypharmacology in anticancer therapy -- 6 Advanced drug delivery systems -- 7 Stimuli-responsive drug delivery systems -- 7.1 pH-responsive -- 7.2 Light-responsive -- 7.3 Redox-responsive
|
| 505 |
8 |
|
|a 7.4 Enzyme-responsive -- 8 Conclusion and future perspectives -- References -- Chapter 5 Target drug delivery in cancer -- 1 Introduction -- 2 Ligand-mediated targeting (surface modification) -- 2.1 Peptide as targeting ligand -- 2.2 Aptamer-mediated drug targeting -- 2.3 Small molecule-mediated targeted drug delivery -- 2.3.1 Folate receptor targeting -- 2.3.2 Anisamide-mediated targeting -- 2.3.3 Sugar-mediated targeting -- 3 Protein-mediated targeting -- 3.1 Antibody-mediated targeting -- 3.2 Transferrin-mediated targeting -- 3.3 Lectin-mediated drug delivery
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|x methods
|0 (DNLM)D016503Q000379
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Cancer
|x Chimioth�erapie.
|0 (CaQQLa)201-0004691
|
| 650 |
|
7 |
|a Cancer
|x Chemotherapy
|2 fast
|0 (OCoLC)fst00845327
|
| 650 |
|
7 |
|a Drug delivery systems
|2 fast
|0 (OCoLC)fst00898667
|
| 700 |
1 |
|
|a Dua, Kamal.
|
| 776 |
0 |
8 |
|i Ebook version :
|z 9780323900799
|
| 776 |
0 |
8 |
|i Print version:
|t Advanced drug delivery systems in the management of cancer.
|d London : Academic Press, 2021
|z 0323855032
|z 9780323855037
|w (OCoLC)1231959699
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323855037
|z Texto completo
|
